Abstract: The present invention relates to a microorganism-based cosmetic composition containing, as an active ingredient, at least one of a fermentation product of Lactococcus lactis, a fermentation product of Limosilactobacillus reuteri, and a fermentation product of Saccharomyces cerevisiae, and containing a fermentation product of Lactiplantibacillus plantarum as an active ingredient, as well as a method for producing the same.

Abstract: An encoding/decoding apparatus and method for parallel correction of in-loop pixels based on complexity using a video parameter may include a complexity measuring unit to measure a complexity of an in-loop pixel correction process, using video codec parameter information, in a video codec, and a core allocating unit to evenly distribute jobs associated with the in-loop pixel correction process, using the measured complexity.

Abstract: A sample adaptive offset (SAO) processing apparatus reusing an input buffer and an operation method of the SAO processing apparatus may include a SAO parameter parser to parse SAO parameter information from a bitstream; a SAO parameter adjuster to extract SAO type information and offset information from the parsed SAO parameter information; and a filtering performer to perform filtering on the bitstream based on the SAO type information and the offset information.

Abstract: An apparatus and method for in-loop filtering based on a largest coding unit (LCU) to reduce an external memory access bandwidth. An in-loop filter may include an external memory to store decoded frames, an internal memory to store pixels in use for deblocking filtering and sample adaptive offset filtering, a horizontal deblocking filter to perform deblocking filtering on input pixels in a horizontal direction with respect to vertical edge boundaries within an input area, a vertical deblocking filter to perform deblocking filtering in a vertical direction with respect to horizontal edge boundaries within the input area, and a sample adaptive offset filter to perform sample adaptive offset filtering.

Abstract: The present invention relates to an entropy encoding method comprising the following steps: updating probability information using the update information derived based on a bit stream received from an encoder; deriving a bin corresponding to the current codeword based on the updated probability information; and performing the inverse binarization of the derived bin to acquire a syntax element. According to the present invention, video-encoding/decoding efficiency may be improved.

Abstract: An encoding/decoding apparatus and method for parallel correction of in-loop pixels based on complexity using a video parameter may include a complexity measuring unit to measure a complexity of an in-loop pixel correction process, using video codec parameter information, in a video codec, and a core allocating unit to evenly distribute jobs associated with the in-loop pixel correction process, using the measured complexity.

Abstract: A deblocking filtering apparatus and method based on raster scanning is provided. The deblocking filtering apparatus may include a boundary determining unit to determine whether at least one of a vertical edge boundary and a horizontal edge boundary of a block corresponds to at least one of a coding unit (CU) boundary, a transform unit (TU) boundary, and a prediction unit (PU) boundary, a boundary strength (BS) computing unit to compute a BS value for at least one of the vertical edge boundary and the horizontal edge boundary when at least one of the vertical edge boundary and the horizontal edge boundary of the block corresponds to at least one of the CU boundary, the TU boundary, and the PU boundary as a result of the determining, and a filtering performing unit to perform deblocking filtering on at least one of the vertical edge boundary and the horizontal edge boundary.

Abstract: A method for treating a VCAM-1 mediated disease comprising administering a therapeutically effective amount of a monoclonal antibody to a patient in need thereof. The monoclonal antibody specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1). The monoclonal antibody comprises(a) a light chain CDR 1 region defined by SEQ ID NO:5, a light chain CDR 2 region defined by SEQ ID NO:6, and a light chain CDR 3 region defined by SEQ ID NO:7, and (b) a heavy chain CDR 1 region defined by SEQ ID NO:8, a heavy chain CDR 2 region defined by SEQ ID NO:.9 or 11, and a heavy chain CDR 3 region defined by SEQ ID NO:10 or 12.

Abstract: The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody that specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1), a method for producing the same, a composition for diagnosis or treatment comprising them and a method for diagnosis or treatment using them. The monoclonal antibody of the present invention is the first recombinant monoclonal antibodies that is specific to human and mouse VCAM-1. In addition, the monoclonal antibody of the present invention shows a strong affinity to VCAM-1 expressed in rat skeletal muscle and porcine endothelial cells as well as human and mouse endothelial cells and is found to strongly inhibit the interaction between leukocytes and activated endothelial cells.

Abstract: The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody that specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1), a method for producing the same, a composition for diagnosis or treatment comprising them and a method for diagnosis or treatment using them. The monoclonal antibody of the present invention is the first recombinant monoclonal antibodies that is specific to human and mouse VCAM-1. In addition, the monoclonal antibody of the present invention shows a strong affinity to VCAM-1 expressed in rat skeletal muscle and porcine endothelial cells as well as human and mouse endothelial cells and is found to strongly inhibit the interaction between leukocytes and activated endothelial cells.